NYSE - Delayed Quote • USD
Taro Pharmaceutical Industries Ltd. (TARO)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:16 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | -- | 1 | -- |
Avg. Estimate | 0.31 | 0 | 1.1 | 0 |
Low Estimate | 0.31 | 0 | 1.1 | 0 |
High Estimate | 0.31 | 0 | 1.1 | 0 |
Year Ago EPS | 0.18 | 0.27 | 0.68 | 1.1 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | -- | 1 | -- |
Avg. Estimate | 156.06M | -- | 618.06M | -- |
Low Estimate | 156.06M | -- | 618.06M | -- |
High Estimate | 156.06M | -- | 618.06M | -- |
Year Ago Sales | 146.59M | -- | 572.95M | 618.06M |
Sales Growth (year/est) | 6.50% | -- | 7.90% | -- |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.23 | 0.31 | 0.18 | 0.3 |
EPS Actual | 0.18 | 0.27 | 0.23 | 0.54 |
Difference | -0.05 | -0.04 | 0.05 | 0.24 |
Surprise % | -21.70% | -12.90% | 27.80% | 80.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.31 | 0 | 1.1 | 0 |
7 Days Ago | 0.31 | 0 | 1.1 | 0 |
30 Days Ago | 0.31 | 0 | 1.1 | 0 |
60 Days Ago | 0.31 | 0 | 1.1 | 0 |
90 Days Ago | 0.31 | 0 | 1.1 | 0 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | TARO | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 72.20% | -- | -- | 6.50% |
Next Qtr. | -- | -- | -- | 12.00% |
Current Year | 61.80% | -- | -- | 5.30% |
Next Year | -- | -- | -- | 13.10% |
Next 5 Years (per annum) | -12.95% | -- | -- | 11.09% |
Past 5 Years (per annum) | -33.80% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Downgrade | HC Wainwright & Co.: Buy to Neutral | 1/18/2024 |
Maintains | HC Wainwright & Co.: Buy | 1/25/2023 |
Maintains | HC Wainwright & Co.: Buy | 8/15/2022 |
Maintains | HC Wainwright & Co.: Buy | 1/31/2022 |
Maintains | HC Wainwright & Co.: Buy | 1/18/2022 |
Maintains | HC Wainwright & Co.: Buy | 7/28/2021 |
Related Tickers
KMDA Kamada Ltd.
5.15
-0.96%
PBH Prestige Consumer Healthcare Inc.
70.47
+0.47%
KLAR.ST Klaria Pharma Holding AB (publ.)
0.3290
+7.87%
LVRLF CordovaCann Corp.
0.0890
0.00%
SPR.CN Sproutly Canada Inc.
0.0200
0.00%
IRWD Ironwood Pharmaceuticals, Inc.
7.82
-3.22%
LFCR Lifecore Biomedical, Inc.
6.60
-0.68%
PCRX Pacira BioSciences, Inc.
26.33
+3.25%
SSIC Silver Spike Investment Corp.
11.18
+0.70%
COLL Collegium Pharmaceutical, Inc.
36.42
+1.62%